Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
| Status: | Completed |
|---|---|
| Conditions: | Ovarian Cancer, Cancer, Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 8/15/2012 |
| Start Date: | August 2012 |
| End Date: | December 2013 |
| Contact: | Ursula A Matulonis, MD |
| Email: | Ursula_Matulonis@dfci.harvard.edu |
| Phone: | 617-632-2334 |
Phase II Study of Single Agent Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer With No Prior PARP Exposure or Prior PARP Inhibitor Exposure
This research study is a way of gaining new knowledge about a drug called olaparib in women
who have either: 1)never received a PARP inhibitor before to treat ovarian cancer (group 1)
or 2)participants who have received a PARP inhibitor before to treat ovarian cancer, with
the exception of olaparib (group 2). PARP inhibitors are drugs tht prevent cancer cells from
repairing their DNA. In this research study, we are looking to see how well the drug
olaparib works in women who have never received a PARP inhibitor for recurrent ovarian
cancer as well as those who have received a prior PARP inhibitor and whose cancer has
re-grown after receiving that PARP inhibitor.
Olaparib tablets will be taken twice daily, orally, in treatment cycles lasting 4 weeks.
On days 1, 8, 12 and 22 of the first 2 cycles and day 1 of all other cycles, subjects will
have a physical exam, be asked questions about their general health, and specific questions
about any problems they might be having and any medications they are taking.
Tumor will be assess by either CT or MRI scan every 2 cycles (every 2 months). Tumor
biopsies will be optional in this study. Only participants that have received a PARP
inhibitor in the past will be asked to have a biopsy of their tumor.
Inclusion Criteria:
- Histologically confirmed ovarian, peritoneal or fallopian tube cancer that has
recurred following a platinum-based regimen used at initial diagnosis
- Measurable disease
- Estimated life expectancy greater than 16 weeks
- Normal organ and marrow function
- Evidence of non-childbearing status for women of childbearing potential
- Able to swallow oral medication
Exclusion Criteria:
- Pregnant or breastfeeding
- Prior PARP inhibitor use for another cancer such as breast cancer
- Receiving any other study agents or any other anti-cancer treatment
- Known brain metastases
- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to olaparib
- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive hear failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements
- History of a different malignancy unless disease-free for at least 5 years
- Currently experiencing seizures or currently being treated with any anti-epileptic
for seizures
- Human immunodeficiency virus (HIV) positive on combination antiretroviral therapy
- Presence of gastrointestinal disorders that, in the investigator's opinion, are
likely to interfere with the absorption of olaparib, or with the patient's ability to
take regular oral medication
We found this trial at
1
site
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
